NOW
ENROLLING
The COSMIC-313 study investigates cabozantinib with nivolumab and
ipilimumab vs nivolumab and ipilimumab alone, in advanced, treatmentnaive
renal cell carcinoma. This study is part of the COSMIC Trials program
evaluating cabozantinib, alone or in combination with immune checkpoint
inhibitors, for the treatment of solid tumors. Learn more at COSMIC313.com
Eligibility
This study is currently enrolling patients who have not received prior systemic
therapy for unresectable locally advanced or metastatic renal cell carcinoma
with a clear cell component. Patients must meet additional inclusion and
exclusion criteria to be eligible for enrollment.
Learn more at ClinicalTrials.gov or contact Exelixis Medical Information
at 1-888-EXELIXIS (1-888-393-5494). NCT03937219.
THE COMBINATION OF CABOZANTINIB WITH NIVOLUMAB AND IPILIMUMAB
IS NOT APPROVED FOR THE USE UNDER INVESTIGATION
©2020 Exelixis_COSMIC 313_HCP Print Ad Copy_v1_30Jan2020
/COSMIC313.com
/ClinicalTrials.gov